SOPHIA Genetics Raises FY25 Revenue Guidance to $72M-$76M

Sophia Genetics has backed its FY25 revenue view of $72M-$76M, in line with consensus of $74.2M. The company also expects a FY25 adjusted EBITDA loss of $35M-$39M. Sophia Genetics signed 35 new core genomics customers in Q2 and announced a multi-year AI breast cancer partnership with AstraZeneca, its largest contract to date.

Sophia Genetics SA (NASDAQ: SOPH), a leading cloud-native software company specializing in data-driven medicine, has reported its Q2 2025 financial results. The company delivered strong revenue growth and announced significant business wins, reaffirming its full-year 2025 (FY25) revenue and adjusted EBITDA loss views.

Q2 2025 Financial Results

- Revenue: Sophia Genetics reported $18.3 million in revenue for Q2 2025, up 16% year-over-year (YoY) [2].
- Gross Margin: The company's gross margin increased to 74.4% on an adjusted basis, up from 73.2% in the prior year period [2].
- Net Loss: IFRS net loss increased 48% YoY to $22.4 million (or 23% excluding foreign exchange impact) [2].
- Cash Burn: Cash burn improved 35% to $8.7 million (or 10% excluding foreign exchange impact) [2].

Business Highlights

- New Customers: Sophia Genetics signed 35 new core genomics customers in Q2 2025, bringing the total to 490 customers as of June 30, 2025 [2].
- Liquid Biopsy Application: The company recorded the first wave of material volume from its new Liquid Biopsy application, MSK-ACCESS® powered with SOPHiA DDMTM, carrying higher-than-average selling prices [2].
- AstraZeneca Partnership: Sophia Genetics announced its largest contract to date, a multi-year AI breast cancer partnership with AstraZeneca, which leverages the company's multimodal AI factories to optimize breast cancer patient outcomes [2].

FY25 Outlook

Sophia Genetics reaffirmed its FY25 revenue guidance of $72 million to $76 million, representing growth of approximately 10% to 17% compared to FY2024 [2]. The company expects a FY25 adjusted EBITDA loss of $35 million to $39 million, compared to $40.2 million in FY2024 [2].

Analyst Estimates

Analysts had estimated Q2 2025 revenue at $17.48 million and earnings at -$0.23 per share. The full-year 2025 revenue estimate was $74.20 million, and earnings were expected to be -$0.92 per share [1].

References

[1] https://finance.yahoo.com/news/sophia-genetics-sa-soph-q2-140745446.html

[2] https://www.morningstar.com/news/pr-newswire/20250805ne43750/sophia-genetics-reports-second-quarter-2025-results